Increase in the number ofpatients suffering from various kidney disorders such as acute kidney injury(AKI), chronic kidney disease (CKD), nephropathies, and drug-induced kidneytoxicities has led to development of novel renal biomarkers to better managedisease progression rate. Renal biomarkers are used to localize kidney injury(i.e., at the glomerular level, tubular level, or both) and differentiate renalinjury from pre-, post-, and non-renal injury. These biomarkers can alsopredict severity of renal injury and monitor the effects of intervention.
The global RenalBiomarkers Market is estimated to account for US$ 1,094.5 Mn in terms ofvalue in 2019 and is expected to reach US$ 1,894.2 Mn by the end of 2027.
Global Renal Biomarkers Market:Drivers
Increasing demand for earlydiseases diagnosis of various kidney diseases is expected to propel growth ofthe global renal biomarkers market over the forecast period. Renal biomarkersoffer early diagnosis of kidney injury and provide better information about thestatus of ongoing injury in patients with chronic kidney disease. Thesebiomarkers also forecast the probability of progression of disease, which helpsin development of personalized medicine for the treatment of chronic kidneydisease.
Global Renal Biomarkers Market:Opportunities
Use of renal biomarkers for thediagnosis of renal cancer is expected to offer lucrative growth opportunitiesfor players in the global renal biomarkers market over the forecast period.Renal biomarkers can be effective in diagnosis of renal cancer. Currently manyclinical and laboratory algorithms are being used but there is no perfect toolfor early diagnosis of renal cancer and tumors, that are thought to beaccidently detected during routine abdominal imaging. Early diagnosis of renalcancer can prevent disease progression.
Global Renal Biomarkers Market:Restraints
Lack in validation of novel renalbiomarkers and their inability to correlate with clinical outcomes is expectedto hinder growth of the global biomarker. Majority of renal biomarkerscurrently in use elevate too late and thus, they cannot be easily co-relatedwith biologic or clinical outcomes. Moreover, renal biomarkers available today are indicative of renal functionmore than being a marker of renal injury and are affected by non-renalparameters such as gender, age, and medication status, which makes it moredifficult to manage acute kidney injury (AKI).
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3551
Key Takeaways:
Functional biomarkers segment inthe global renal biomarkers market was valued at US$ 543.6 Mn in 2018 and isexpected to reach US$ 1,057.3 Mn by 2027 at a CAGR of 7.6% during the forecastperiod. Increasing products, and assay launches is expected to support growthof the segment over the forecast period. For instance, Sphingotec launchedpenKid point-of-care (POC) biomarker blood test for evaluating kidney functionin January 2020 in CE mark accepted European countries
The Enzyme Linked ImmunosorbentAssay segment held dominant position in the global renal biomarkers market in2018, accounting for 44.3% share in terms of value, followed byParticle-Enhanced Turbidimetric Immunoassay and Colorimetric Assay,respectively. Enzyme Linked Immunosorbent Assay (ELISA) is immunoassay used toidentify proteins, peptides, antibodies, and hormones. Moreover, majority ofkidney biomarker tests involve use of enzyme linked immunosorbent assaytechnique which is expected to support growth of the segment over the forecastperiod.
The diagnostic labs segment helddominant position in the global renal biomarkers market in 2018, accounting for34.9% share in terms of value, followed by Outpatient Clinics and ResearchCenters, respectively. Diagnostic laboratories is the primary end user wherekidney biomarker tests are performed in bulk. Physicians often recommend kidneydisease patients to have diagnostic tests performed in central diagnosticlaboratories.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/renal-biomarkers-market-3551
Market Trends
Various government organizationsoffer grants for R&D in renal diseases. For instance, in September 2018,the National Institute of Diabetes and Digestive and Kidney Diseases, a part ofDepartment of Health and Human Services - National Institutes of Health,awarded Yale University grant for ‘Identification of Non-invasive Biomarkersand Indices for Diagnosis of Drug-Induced Acute Interstitial Nephritis.
R&D of biomarkers for kidneyallergic reaction is expected to boost growth of the market. For instance, inMay 2019, researchers from Johns Hopkins Medicine (U.S) reported identifyingtwo protein biomarkers in urine, Urine TNF-α and IL-9’, for effective diagnosisof acute interstitial nephritis.
Global Renal Biomarkers Market:Competitive Landscape
Major players operating in theglobal renal biomarkers market include, Beckman Coulter, Inc., (DanaherCorporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S,Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.
Global Renal Biomarkers Market:Key Developments
January 2020: Hitado GmbH, aSysmex point-of-care subsidiary, and SphingoTec GmbH signed an exclusivedistribution agreement for the commercialization of the Nexus IB10 diagnosticplatform, a fully automated rapid immunoassay point-of-care platform by Hitado,in Germany
October 2019: Antech Diagnosticsacquired Biovet, a biotechnology company that offers diagnostic solutions foranimal health
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3551
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
